UBS Group Raises BioNTech (NASDAQ:BNTX) Price Target to $131.00

BioNTech (NASDAQ:BNTX) had its price target upped by UBS Group from $97.00 to $131.00 in a research report report published on Wednesday, Benzinga reports. They currently have a neutral rating on the stock.

Other analysts have also issued research reports about the stock. HC Wainwright reissued a buy rating and issued a $113.00 price target on shares of BioNTech in a report on Monday, September 16th. HSBC upgraded BioNTech from a hold rating to a buy rating in a report on Friday, August 2nd. Bank of America boosted their price objective on BioNTech from $125.00 to $150.00 and gave the stock a buy rating in a report on Monday, September 16th. TD Cowen lowered their price target on shares of BioNTech from $98.00 to $85.00 and set a hold rating for the company in a research report on Tuesday, August 6th. Finally, JPMorgan Chase & Co. raised shares of BioNTech from an underweight rating to a neutral rating and raised their price objective for the company from $91.00 to $125.00 in a research note on Monday, September 16th. Six equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of Moderate Buy and a consensus price target of $124.54.

BioNTech Stock Down 0.2 %

NASDAQ BNTX opened at $112.28 on Wednesday. The stock’s 50 day simple moving average is $90.81 and its 200 day simple moving average is $90.63. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.54 and a quick ratio of 7.40. BioNTech has a one year low of $76.53 and a one year high of $131.49. The firm has a market cap of $26.69 billion, a PE ratio of 224.56 and a beta of 0.23.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings results on Monday, August 5th. The company reported ($3.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.02) by ($1.34). BioNTech had a negative net margin of 18.69% and a negative return on equity of 2.54%. The business had revenue of $128.70 million during the quarter, compared to the consensus estimate of $134.98 million. During the same period in the prior year, the firm earned ($0.86) earnings per share. The business’s quarterly revenue was down 23.3% compared to the same quarter last year. As a group, sell-side analysts forecast that BioNTech will post -2.8 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BioNTech

Institutional investors have recently modified their holdings of the business. Harding Loevner LP acquired a new stake in BioNTech during the 4th quarter worth approximately $410,984,000. Candriam S.C.A. lifted its position in BioNTech by 261.2% in the 2nd quarter. Candriam S.C.A. now owns 578,998 shares of the company’s stock valued at $46,526,000 after acquiring an additional 418,695 shares in the last quarter. Point72 Asset Management L.P. boosted its stake in BioNTech by 283.5% in the 2nd quarter. Point72 Asset Management L.P. now owns 461,711 shares of the company’s stock worth $37,103,000 after purchasing an additional 341,311 shares during the period. Primecap Management Co. CA increased its holdings in BioNTech by 2.8% during the 4th quarter. Primecap Management Co. CA now owns 4,763,453 shares of the company’s stock worth $502,735,000 after purchasing an additional 131,490 shares in the last quarter. Finally, SG Americas Securities LLC raised its stake in shares of BioNTech by 610.5% in the 1st quarter. SG Americas Securities LLC now owns 70,143 shares of the company’s stock valued at $6,471,000 after purchasing an additional 60,270 shares during the period. Institutional investors own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.